Relay Therapeutics
RLAY
131 hedge funds and large institutions have $3.41B invested in Relay Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 70 increasing their positions, 20 reducing their positions, and 18 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 20
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
18% more capital invested
Capital invested by funds: $2.89B → $3.41B (+$513M)
3.72% more ownership
Funds ownership: 99.01% → 102.73% (+3.7%)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
1% less funds holding
Funds holding: 132 → 131 (-1)
91% less call options, than puts
Call options by funds: $248K | Put options by funds: $2.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$80.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$79.6M |
| 3 |
JP Morgan Chase
New York
|
+$61.3M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$50.3M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$43.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$6.05M |
| 2 |
Renaissance Technologies
New York
|
-$4.6M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
-$2.44M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.21M |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
-$1.88M |
RLAY Hedge Fund Activity: Q4 2021 in Review
131 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q4 2021, worth a combined $3.41B — up 18% from $2.89B a quarter earlier.
Fund positioning in RLAY was balanced in Q4 2021: 18 funds opened new positions, 18 closed out, 70 added to existing stakes and 20 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $80.2M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $6.05M sold.
- 131 institutional investors held Relay Therapeutics (RLAY) as of Q4 2021, down from 132 in Q3 2021.
- Funds reported $3.41B of Relay Therapeutics stock for Q4 2021, up 18% quarter-over-quarter.
- 18 funds opened new Relay Therapeutics positions in Q4 2021 and 18 closed out, a net change of 0 holders.
- The largest Relay Therapeutics buyer in Q4 2021 was T. Rowe Price Associates, an estimated $80.2M added.
- The largest Relay Therapeutics seller in Q4 2021 was Two Sigma Investments, an estimated $6.05M sold.
Based on aggregated 13F filings for Q4 2021.